GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other Benefits When Combined With Bortezomib
Pharmacy Times,
A study published in Oncotarget examined the efficacy of GZ17-6.02 in multiple myeloma cells.
A study published in Oncotarget examined the efficacy of GZ17-6.02 in multiple myeloma cells.
A new research paper titled "GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells" has been published…
image: Figure 7: ER stress signaling plays an important role in mediating GZ17-6.02/bortezomib lethality view more Credit: 2024…
“We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities…